Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Simon Property Group Inc (SPG) Price & Performance

Abeona Therapeutics IncTrade
Simon Property Group IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Simon Property Group Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Simon Property Group Inc trades at $219.2 (market cap $71.03B). The key difference: Simon Property Group Inc is far larger — about 168.6× Abeona Therapeutics Inc's market cap, and Simon Property Group Inc pays a 4.05% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEOSPG
Market Cap
$421.19M$71.03B
Sector
HealthReal Estate
52-Week High
$7.45$236.70
52-Week Low
$4.17$169.22
Enterprise Value
$276.10M$99.48B
Dividend Yield
4.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Simon Property Group Inc

SPG trades at $220.55, down 1.06% with a bearish technical signal. The REIT shows strong fundamentals with Q2 2026 FFO beating estimates at $3.29 per share and raised full-year guidance. Valuation metrics appear reasonable with P/E of 15.49 and EV/EBITDA of 11.96, while profitability remains robust with 66.57% net margin and 135.7% ROE. Recent news highlights leasing strength and retailer sales growth driving performance.

The outlook remains positive with analyst consensus at Buy (40.54%) and $226.58 price target offering 2.7% upside. Key risks include interest rate sensitivity from $24.21B debt load and retail sector headwinds. Strong cash flow generation and dividend consistency support the investment case for income-focused investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Simon Property Group Inc

Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.

Read more on SPG